Earlier studies showed that SW620 and HT29 are resistant to EGFR inhibition (cetuximab) [43], which corresponds to the lack of activity of erlotinib on tumor growth, as well as on the metabolic activity and apoptosis demonstrated here. Here, EGFR is linked to neoplasm.